Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary G-CSF Prophylaxis in Breast Cancer
NCT00536081Phase 3Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegfilgrastim in febrile neutropenia (FN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Number of febrile neutropenia episodes at 18 weeks and Costs per treatment arm at 18 weeks. Started Jan 2008; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00536081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00536081.